Efficacy and Tolerance of HCV Treatment in HIV-HCV Coinfected Patients: The Potential Interaction of PI Treatment

REFERENCES

• Di Martino V, Rufat P, Boyer N, et al. The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospec-tive cohort study. Hepatology. 200134: 1193–1199.
   Google Scholar
• Pol S, Fontaine H, Carnot F, et al. Predictive factors for development of cirrhosis in parenterally acquired chronic hepatitis C: a comparison between immunocompetent and immunocompromised patients. J Hepatol. 1998;29:12–19.
   PubMed Web of Science ®Google Scholar
• Poynard T, Leroy V, Cohard M, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepati-tis C: effects of dose and duration. Hepatology. 1996;24:778–789.
   PubMed Web of Science ®Google Scholar
• Soto B, Sanchez-Quijano A, Rodrigo L, et al. Human immu-nodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol. 1997;26:1–5.
   PubMed Web of Science ®Google Scholar
• Garcia-Samaniego J, Rodriguez M, Berenguer J, et al. Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. Am JGastroenteroL 2001;96:179–183.
   PubMed Web of Science ®Google Scholar
• Poles MA, Dieterich DT. Hepatitis C virus/human immuno-deficiency virus coinfection: clinical management issues. Clin Infect Dis. 2000;31:154–161.
   PubMed Web of Science ®Google Scholar
• Soriano V, Garcia-Samaniego J, Rodriguez-Rosado R, Gonzalez J, Pedreira J. Hepatitis C and HIV infection: biological, clinical, and therapeutic implications. J Hepatol. 1999;31(suppI1):199–123.
   Google Scholar
• Puoti M, Spinetti A, Ghezzi A, et al. Mortality for liver disease in patients with HIV infection: a cohort study. J Acquir Immune Defic Syndr. 2000;24:211–217.
   PubMed Web of Science ®Google Scholar
• Darby SC, Ewart DW, Giangrande PL, et al. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. Lancet. 1997;350:1425–1431.
   PubMed Web of Science ®Google Scholar
• Sulkowski MS, Mast EE, Seeff LB, Thomas DL. Hepatitis C virus infection as an opportunistic disease in persons in-fected with human immunodeficiency virus. Clin Infect Dis. 2000;30:S77–84.
   PubMed Web of Science ®Google Scholar
• Nunez M, Lana R, Mendoza JL, Martin-Carbonero L, Soriano V. Risk for severe hepatic injury after introduction of Highly Active Antiretroviral Therapy. J Acquir Immune Defic Syndr. 200127: 426–431.
   Google Scholar
• Saves M, Vandentorren S, Daucourt V, et al. Severe he-patic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations. Aquitaine Cohort, 1996-1998. AIDS. 1999;13:F115–121.
   PubMed Web of Science ®Google Scholar
• Pol S. Management of hepatitis C viral infection in HIV-positive patients taking antiretroviral treatment. Presse Med. 2001;30:677–682.
   PubMed Web of Science ®Google Scholar
• Expert group. Coinfection par le VIH et le VHC. In: Delfraissy J, ed. Prise en charge therapeutique des personnes infectees par le VIH. Recommandations du groupe d'experts. Paris: Médecine-Sciences/Flammarion; 2000:77–80.
   Google Scholar
• Dodig M, Tavill AS. Hepatitis C and human immunodefi-ciency virus coinfections. J Clin Gastroenterol. 2001;33:367–374.
   PubMed Web of Science ®Google Scholar
• Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. New Engl J Med. 2002;347:975–982.
   PubMed Web of Science ®Google Scholar
• Mc Hutchison JG, Gordon SC, Schiff ER, et al. Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. New Engl J Med. 1998;339:1485–1492.
   PubMed Web of Science ®Google Scholar
• Reichard 0, Norkrans G, Fryden A, Braconier JH, Sonnerborg A, Weiland 0. Randomised, double-blind, pla-cebo-controlled trial of interferon alpha-2b with and with-out ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet. 1998;351:83–87.
   PubMed Web of Science ®Google Scholar
• Landau A, Batisse D, Piketty C, et al. Long-term efficacy of combination therapy with interferon-alpha 2b and ribavirin for severe chronic hepatitis C in HIV-infected patients. AIDS. 2001;15:2149–2155.
   PubMed Web of Science ®Google Scholar
• Nasti G, Di Gennaro G, Tavio M, et al. Chronic hepatitis C in HIV infection: feasibility and sustained efficacy of therapy with interferon alfa-2b and ribavirin. AIDS. 200115:1783–1787.
   Google Scholar
• Marcellin P. Hepatitis C: the clinical spectrum of the dis-ease. J Hepatol. 1999;31(suppI1):9–16.
   PubMed Web of Science ®Google Scholar
• Thélot B, Pialoux G, Delhommeau A, Piroth L, Salmon-Céron D, APPIT. Epidémiologie hospitalière des patients coinfectés par le VIH et le VHC. Bull Epidemiol Hebd. 2000;(39):1–5.
   Google Scholar
• Consensus Panel. EASL International Consensus Confer-ence on Hepatitis C: consensus statement. J Hepatol. 1999;31(suppI1):3–8.
   PubMedGoogle Scholar
• Goebel FD, Jablonowski H. Therapy of special HIV-associ-ated diseases: HCV-HIV-co-infection and AIDS-related Kaposi's sarcoma. Eur J Med Res. 1999;4:507–513.
   PubMedGoogle Scholar
• Simmonds P. Viral heterogeneity of the hepatitis C virus. J Hepatol. 1999;31\(suppl 1):54–60.
   PubMed Web of Science ®Google Scholar
• Mondelli MU, Silini E. Clinical significance of hepatitis C virus genotype. J Hepatol. 1999;31\(suppl 1):65–70.
   PubMed Web of Science ®Google Scholar
• Fernandez I, Rubio R, Lumbreras C. Hepatitis C in HIV-infected patients-therapeutic approach. Clin Microbiol In-fect. 2002;8:80–84.
   PubMed Web of Science ®Google Scholar
• Benhamou Y, Di Martino V, Bochet M, et al. Factors affect-ing liver fibrosis in human immunodeficiency virus- and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology. 2001;34:283–287.
   PubMed Web of Science ®Google Scholar
• Trimoulet P, Neau D, Le Bail B, et al. Intrahepatic HCV RNA loads in 37 HIV-HCV co-infected patients with controlled HIV infection. J Med ViroL 2002;67:146–151.
   Web of Science ®Google Scholar
• Soriano V, Rodriguez-Rosado R, Garcia-Samaniego J. Management of chronic hepatitis C in HIV-infected pa-tients. AIDS. 1999;13:539–546.
   PubMed Web of Science ®Google Scholar
• Poynard T, McHutchison J, Manns M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology. 2002;122:1303–1313.
   PubMed Web of Science ®Google Scholar